Kenya is intensifying its efforts to establish itself as a regional vaccine manufacturing hub, with the World Bank reaffirming its support for the country’s biopharmaceutical ambitions.
In a meeting with a World Bank delegation, Health Cabinet Secretary Dr. Deborah Mlongo Barasa and Principal Secretary for Medical Services Harry Kimtai emphasized the country’s commitment to vaccine self-sufficiency. The discussion highlighted Kenya’s critical role in regional health security and the importance of developing local production capacity.
“The Bank’s support is informed by key lessons drawn from the COVID-19 pandemic and other global health emergencies, highlighting the urgent need for sustainable local vaccine manufacturing capacity,” the delegation noted.
Kenya’s partnership with the World Bank is expected to catalyze investment in research and development, enhance regulatory systems, and strengthen pandemic preparedness. With its strategic location, the country is well-positioned to serve the wider East and Central African region, improving access to affordable vaccines while reinforcing public health resilience.
“With continued support from the World Bank, Kenya is poised to become a regional hub for vaccine production—promoting self-sufficiency, reducing reliance on imports, and fostering the growth of the biopharmaceutical sector,” the officials stated.
The collaboration between the Kenyan government, private sector, and global partners signals a shift towards innovation-driven healthcare. In the long term, Kenya aims to transition from vaccine importation to domestic production and eventual exports, solidifying its status as a key player in global health security.
